Results 111 to 120 of about 67,507 (290)

Treatment Response and Outcomes of Prostate Cancer Patients Carrying the Germline MMS22L F722fs Mutation

The Prostate, EarlyView.
ABSTRACT Background Methyl Methanesulfonate‐Sensitivity Protein 22‐Like (MMS22L) plays a key role in homology‐directed DNA repair, and experimental models have shown that its loss confers sensitivity to Poly (ADP‐ribose) polymerase inhibitors (PARPi).
Mayuko Kanayama, Violet A. Daniels, Marta Gielzak, Alex Brame, Misop Han, Li Jia, Jianfeng Xu, Tamara L. Lotan, Mario A. Eisenberger, Catherine H. Marshall, Patrick C. Walsh, William B. Isaacs, Jun Luo   +12 more
wiley   +1 more source

Androgen receptors beyond prostate cancer: an old marker as a new target. [PDF]

, 2014
Androgen receptors (ARs) play a critical role in the development of prostate cancer. Targeting ARs results in important salutary effects in this malignancy.
Kurzrock, Razelle, Munoz, Javier, Wheler, Jennifer J   +2 more
core   +2 more sources

Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases Analysis

The Prostate, EarlyView.
ABSTRACT Background In prostate cancer (PCa), smoking history is associated with more aggressive clinicopathological features, reduced efficacy of androgen deprivation therapy, and poorer overall survival (OS). However, its impact on survival outcomes in patients receiving taxane chemotherapy, poly ADP‐ribose polymerase inhibitor (PARPi), or immune ...
Tomoya Hatayama, Yohei Sekino, Go Kobayashi, Kazuma Yukihiro, Yoshinori Nakano, Shinsaku Tasaka, Naofumi Nomura, Yuki Kohada, Kenshiro Takemoto, Miki Naito, Shunsuke Miyamoto, Kohei Kobatake, Hiroyuki Kitano, Keisuke Goto, Akihiro Goriki, Keisuke Hieda, Nobuyuki Hinata   +16 more
wiley   +1 more source

Corticosteroid Use and Risk of Adverse Events in Metastatic Hormone‐Sensitive Prostate Cancer

The Prostate, EarlyView.
ABSTRACT Background Among the approved therapies for metastatic hormone‐sensitive prostate cancer (mHSPC), abiraterone and docetaxel are administered concomitantly with corticosteroids. This study evaluated the association between corticosteroid use and risk of adverse events among patients with mHSPC. Methods We conducted an observational cohort study
Umang Swami, Qiujun Shao, Tamuno Alfred, Maelys Touya, Frank Cao, Pinal Kamdar, Jasmina Ivanova, Johanna Celli, David Nimke   +8 more
wiley   +1 more source

[18F] PSMA PET‐CT and [18F] Choline PET‐CT in the Diagnosis of High‐Risk Localized Prostate Cancer: Comparation of Both Tests

The Prostate, EarlyView.
ABSTRACT Background To compare choline PET‐CT and PSMA PET‐CT in a cohort of patients with high‐risk localized prostate cancer, assessing the diagnostic capacity of both tests. whose therapeutic approach could be modified based on the results. Methods An observational study was conducted in 116 patients with high‐risk prostate cancer between January ...
M. A. Tárraga‐Honrubia, A. S. Salinas‐Sánchez, S. Navarro‐Jiménez, M. V. Lorenzo‐Sánchez, P. Carrión‐López, J. M. Giménez‐Bachs   +5 more
wiley   +1 more source

The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy

The Prostate, EarlyView.
ABSTRACT Background Radiographic progression (RP) without prostate‐specific antigen (PSA) elevation has emerged as a clinically important pattern in the androgen receptor pathway inhibitors (ARPI) era, but its prevalence and prognostic significance in real‐world metastatic hormone‐sensitive prostate cancer (mHSPC) cohorts remain unclear.
Takeshi Tsutsumi, Shogo Yamazaki, Takuya Matsuda, Takuya Tsujino, Taizo Uchimoto, Takafumi Yanagisawa, Keiichiro Mori, Wataru Fukuokaya, Fumihiko Urabe, Masanobu Saruta, Atsuhiko Yoshizawa, Shingo Toyoda, Saizo Fujimoto, Kyosuke Nishio, Moritoshi Sakamoto, Tatsuo Fukushima, Ko Nakamura, Kazuki Nishimura, Keita Nakamori, Tomohisa Matsunaga, Yuki Yoshikawa, Ryoichi Maenosono, Kiyoshi Takahara, Teruo Inamoto, Takahiro Kimura, Kazutoshi Fujita, Kazumasa Komura, Haruhito Azuma   +27 more
wiley   +1 more source

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses

Nature Communications, 2018
The functional significance of the observed heterogeneity of androgen receptor (AR) expression in prostate cancer is unknown. Here the authors show AR expression heterogeneity is associated with distinct castration/enzalutamide responses and identify BCL-
Qiuhui Li, Qu Deng, Hsueh-Ping Chao, Xin Liu, Yue Lu, Kevin Lin, Bigang Liu, Gregory W. Tang, Dingxiao Zhang, Amanda Tracz, Collene Jeter, Kiera Rycaj, Tammy Calhoun-Davis, Jiaoti Huang, Mark A. Rubin, Himisha Beltran, Jianjun Shen, Gurkamal Chatta, Igor Puzanov, James L. Mohler, Jianmin Wang, Ruizhe Zhao, Jason Kirk, Xin Chen, Dean G. Tang   +24 more
doaj   +1 more source

Tributyltin Protumorigenic Effects Targeting Prostate Cancer Cell Metabolism, Proliferation, Migration, and Invasion

Environmental Toxicology, EarlyView.
ABSTRACT Prostate cancer (PCa) is an endocrine‐related cancer highly dependent on androgenic signaling. Beyond hormone dependence, extrinsic factors play a significant role in the risk of developing PCa, which raises concern about the influence of environmental compounds such as endocrine‐disrupting chemicals (EDCs). Tributyltin (TBT) is an EDC used in
Mariana Feijó, Luís P. Brás, Catarina M. D. Serra, Lara R. S. Fonseca, Sara Correia, Bruno J. Pereira, Ana P. Duarte, Henrique J. Cardoso, Cátia V. Vaz, Sílvia Socorro   +9 more
wiley   +1 more source

Liquid biopsy in genitourinary oncology: Current clinical applications and future prospects across prostate, bladder, and renal cancers

UroPrecision, EarlyView.
Abstract Liquid biopsy has emerged as a transformative approach in oncology, providing minimally invasive access to tumor‐derived biomarkers with applications across diagnosis, prognosis, therapeutic guidance, and disease monitoring. This literature review synthesizes evidence from 125 studies evaluating circulating tumor DNA, circulating tumor cells ...
Kirolos Eskandar
wiley   +1 more source

Increased expression of YAP1 in prostate cancer correlates with extraprostatic extension. [PDF]

, 2017
Objective:Yes associated protein 1 (YAP1) is a member of the Hippo pathway, acting as a transcriptional coactivator. To elucidate the role of YAP1 and phosphorylated (p)YAP1 in prostate cancer (PCa) tumorigenesis, we investigated their expression in ...
Collak, Filiz Kisaayak, Demir, Ummuhan, Kurum, Esra, Ozkanli, Seyma, Zerk, Pinar Engin   +4 more
core